This feels like an excellent starting point for Tuesday's ORAL Surveillance malignancy discussion. RWE Cohort: HR 1.01 (0.83-1.22) RCT-dup Cohort: HR 1.19 (0.86-1.64) ORAL Surveillance: HR 1.48 (1.04-2.09) Interesting day 4 ahead! great talk @SeoyoungCKim #ACR21 7S413 @RheumNow https://t.co/YSau21goMr